Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis

29 Aug 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial biofilms and quorum sensing
Share to Biological Research and Disease Studies
Share to Cystic Fibrosis Research Advances

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31474496
DOI: 10.1016/j.jcf.2019.08.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosisPMID 31474496Read ↗

Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.Semantic proximity Read ↗

Cystic fibrosis papers of the year 2017.Semantic proximity Read ↗

Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X.Semantic proximity Read ↗

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Semantic proximity Read ↗

Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutationSemantic proximity Read ↗

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosisSemantic proximity Read ↗

Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.Semantic proximity Read ↗

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Updates on the Management of Cystic Fibrosis: Development of Modulators and Advancement of Antibiotic Therapies.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.Semantic proximity Read ↗

Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.